Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says

At meeting on Pacira's Exparel, advisory committee members warn against rushing to adopt products purported to reduce opioid consumption absent long-term longitudinal data showing beneficial public health impacts and clinical data linking reduced opioid use to functional outcomes or other clinical benefit.

High jump
Can sponsors clear the US FDA's high bar? • Source: Koji Kawano

If Pacira Pharmaceuticals Inc.'s US FDA advisory committee experience with Exparel (bupivacaine liposome injectable suspension) is any indication, sponsors seeking to label their products as having opioid-sparing effects may face a high evidentiary bar for making such claims.

Merely showing that a non-opioid product resulted in reduced use of an opioid in a placebo-controlled trial is not enough...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers